1. Established in late 1999 Scientific/clinical resources Ethics committees Regulatory body TT - 2002

2. SAAVI aims to develop an affordable, effective and locally relevant preventative HIV vaccine for southern Africa

3. HIV genetic diversity C C C C C A A A A AG AG AG AE AE AEGG G J J H B B B B B B B D D D D D F F K K C C C C C C C C C C C C C. Williamson et al

4. Making the vaccine Testing the vaccine Ethical issues Advocacy & community Others TT - 2002 Immunology assessment Human Animal

5. What do we expect from an HIV vaccine?

6. “Viral load” in HIV Amount of HIV 5% 90% Progress to AIDS in 5 years

7. Potential end-points of HIV- vaccine efficacy trials

8. TT - 2002 SAAVI Challenges

9. Making the vaccine Testing the vaccine Ethical issues Advocacy & community Others TT - 2002 Immunology assessment Human Animal

10. TT - 2002 Supporters and Funds

11. TT - 2002 1.Good vaccine candidates 2.HIV subtypes 3.Community involvement 4.Ethical studies 5.Access to product 6.Pricing 7.Technology transfer Appropriate Clinical Trials $30 million

12. TT - 2002 Manufacturing 1.Product? 2.When? 3.What dose? 4.Manufacturing plant 5.Personnel 6.Dose price 7.Distribution capacity $350 million Clinical trials lot Bulk supply

13. TT - 2002 1.Government 2.Medicines Control Council 3.Ethics committees 4.Medical aids 5.Life Insurance 6.Blood transfusion services 7.State Vaccine Institute Strategic national alliances

14. TT - 2002 Strategic international alliances 1.NIH 2.HVTN 3.IAVI 4.AAVP 5.EU 6.Public / private

15. CONCLUSIONSCONCLUSIONS SAAVI has dynamic team Different to all other initiatives Committed to excellence Massive / maturing challenges Consolidate and expand TT - 2002